# üß¨ Warfarin Dose Prediction Based on Genetic Risk Score

This project analyzes the influence of genetic variants **CYP2C9** and **VKORC1** on warfarin dosing by converting genotype data into a quantitative **genetic risk score**. The analysis is based on real-world genotype-dosage data from the PharmGKB database.

---

## üìå Backgrounds

Warfarin is a widely used anticoagulant in clinical practice (Xue *et al.*, 2024), primarily for the prevention of clot-related complications such as stroke and venous thromboembolism (VTE) (Wang *et al.*, 2021). It works by inhibiting the vitamin K epoxide reductase (VKOR) enzyme, which prevents the recycling of vitamin K to its active form. This inhibition consequently reduces the production of functional vitamin K‚Äìdependent clotting factors (Jokhab *et al.*, 2025).

As reported by Jokhab *et al*. (2025), single-nucleotide polymorphisms in the VKORC1 gene (rs9923231) contribute to lower dose requirements for warfarin and increase the risk of excessive anticoagulation. VKORC1 plays a crucial role in the reduction of vitamin K, that are essential in blood clotting (Rodr√≠guez-Fern√°ndez *et al.*, 2024). CYP2C9 is the primary enzyme responsible for metabolizing warfarin in the liver (Xue et al., 2024). According to Zhao et al. (2023), specific single-nucleotide polymorphisms in CYP2C9, namely (rs1799853) and (rs1057910), can reduced enzymatic activity and increased risk of bleeding complications. To mitigate this risk, individuals carrying the CYP2C9 (rs1799853) and (rs1057910) variants may require a lower dosage of warfarin (Zhao et al., 2023).



---

## üìå Objectives

- Assess the relationship between **CYP2C9** and **VKORC1** genotypes with therapeutic warfarin dose.
- Translate genotypes into **Genetic Risk Scores (GRS)** for simplified stratification.
- Visualize dose variation across different risk groups.

---

## üìå Methodology

### üì¶ Dataset

- **Source**: [PharmGKB Warfarin Dosing Dataset](https://www.pharmgkb.org/)
- **Key Columns**:
  - `PharmGKB Subject ID`
  - `CYP2C9 Genotype`
  - `VKORC1 genotype: -1639 G>A (3673); chr16:31015190; rs9923231; C/T`
  - `Therapeutic Dose of Warfarin (mg/day)`

### üßº Data Preprocessing

- Selected only important columns for analysis:
  - `"PharmGKB Subject ID"`, `"CYP2C9 Genotype"`, `"VKORC1 genotype: -1639 G>A (3673); chr16:31015190; rs9923231; C/T"`, and `"Therapeutic Dose of Warfarin"`.
- Renamed columns to simpler and readable names:
  - `"PharmGKB Subject ID"` ‚Üí `"ID"`
  - `"CYP2C9*Genotype"` ‚Üí `"CYP2C9"`
  - `"VKORC1 genotype: -1639 G>A (3673); chr16:31015190; rs9923231; C/T"` ‚Üí `"VKORC1 (rs9923231; C/T)"`
  - `"Therapeutic Dose of Warfarin"` ‚Üí `"Dose"`
- Removed rows with missing values in `CYP2C9`, `VKORC1 (rs9923231; C/T)`, or `Dose`
- Standardized genotype formatting:
  - `"*1 / *3"` ‚Üí `"*1/*3"` (no spaces)
- Created a new column: `Risk_score` based on predefined genotype scoring

### üßÆ Genetic Risk Score System

| Gene     | Genotype(s)              | Score |
|----------|--------------------------|-------|
| CYP2C9   | *1/*1                    | 0     |
|          | *1/*2, *1/*3             | 1     |
|          | *2/*3, *3/*3             | 2     |
| VKORC1   | GG                       | 0     |
|          | AG                       | 1     |
|          | AA                       | 2     |

**Total Risk Score = CYP2C9 Score + VKORC1 Score** (Range: 0‚Äì4)

---

## üìå**Results and Visualization**

### Number of Patients per Risk Score

<img width="580" height="455" alt="Number of patients by genetic risk score1" src="https://github.com/user-attachments/assets/e6fe62e3-5e32-46f8-ac80-fcd1ef14c245" />

**Graph 1**: Number of patients by genetic risk score

> Most patients fall within Risk Score 0 to 2. Very few samples exist for scores 3 and 4, indicating data imbalance.
> The dataset shows a clear imbalance in the number of patients across genetic risk scores.
> This imbalance may affect the interpretation of dose trends at higher scores, as small sample sizes (especially for score 4) may not represent the broader population. Interpretations involving high scores should be made with caution

To improve clarity, the countplot is annotated with the exact count values above each bar using `ax.text()`. This helps highlight class imbalance and ensures the data distribution is clearly visible at a glance.


### Distribution of warfarin dose by genetic score

<img width="989" height="590" alt="Distribution of warfarin dose by genetic risk score" src="https://github.com/user-attachments/assets/136f9baf-5a22-405a-bf21-73b8c55a144c" />

**Graph 2**: Distribution of warfarin dose by genetic score

> A clear downward trend is observed in median dose from score 0 to 4. The dots represent outliers ‚Äî patients whose dose needs differ significantly from the rest of the group.

Outliers are detected based on statistical rules (typically values above 1.5 times the interquartile range), and they help identify variation in dose that might be due to other factors such as:

- Age, body weight, or gender
- Drug interactions or comorbidities
- Possible data entry errors

While outliers are valid and expected in real-world data, a filtered version of the plot (with doses ‚â§100 mg/week) is provided to better visualize typical dosing trends across genetic risk scores.


### Average warfarin dose by genetic risk score

<img width="841" height="547" alt="Average warfarin dose by genetic risk score" src="https://github.com/user-attachments/assets/9782051a-5ad8-486c-9640-179a318e2de5" />

**Graph 3**: Average warfarin dose by genetic risk score


> Based on the genetic risk score (0‚Äì4), we analyzed how warfarin dose varies across different levels of genetic sensitivity.

>  **Mean Warfarin Dose by Risk Score:**
> 
    - Risk score 0 ‚Üí ~52‚Äì54 mg/week
    - Risk score 1 ‚Üí ~47‚Äì50 mg/week
    - Risk score 2 ‚Üí ~43‚Äì46 mg/week
    - Risk score 3 ‚Üí ~38‚Äì41 mg/week
    - Risk score 4 ‚Üí ~35‚Äì37 mg/week

> There is a **clear downward trend** in the average dose as the genetic risk score increases. This supports the idea that certain genotypes (e.g. *2/*3 in CYP2C9 or A/A in VKORC1) are associated with **increased sensitivity to warfarin**, requiring lower dosages.

> The line plot with error bars further confirms this pattern with overlapping standard deviations between adjacent scores, indicating some variability but still an overall consistent trend.

### What does the Error Bar mean?

The vertical lines (error bars) represent the **standard deviation**, which tells us how much variation exists within each group.

- **Short error bar** = consistent dose in that group
- **Long error bar** = wider variation in dose needed

When error bars between different scores **don‚Äôt overlap**, it suggests a real difference in average dose.

---

## üìå**Project structure**


## üìå**Conclusion**

This analysis confirms that increasing genetic risk scores (based on **CYP2C9** and **VKORC1**) are generally associated with lower warfarin doses.

This suggests that pre-treatment genetic testing could support safer and more effective warfarin dosing.

> ‚ö†Ô∏è Disclaimer: This project is for educational purposes only. Not intended for clinical decision-making

---

## üìå**References**

Jokhab, S., AlRasheed, M. M., Bakheet, D., AlMomen, A., AlAboud, N., & Kamali, F. (2025). The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients. Frontiers in Pharmacology, 16, 1547142.

Mar, P. L., Gopinathannair, R., Gengler, B. E., Chung, M. K., Perez, A., Dukes, J., Ezekowitz, M. D., Lakkireddy, D.,  Lip, G. Y. H., Miletello, M., Noseworthy. P. A., Reiffe, J., Tisdale, J. E., Olshansky, B.  (2022). Drug interactions affecting oral anticoagulant use. Circulation: arrhythmia and electrophysiology, 15(6), e007956.

Rodr√≠guez-Fern√°ndez, K., Reynaldo-Fern√°ndez, G., Reyes-Gonz√°lez, S., de Las Barreras, C., Rodr√≠guez-Vera, L., Vlaar, C., ... & Mangas-Sanjuan, V. (2024). New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomedicine & Pharmacotherapy, 170, 115977.

Wang, M., Zeraatkar, D., Obeda, M., Lee, M., Garcia, C., Nguyen, L., Agarwal, A., Al-Shalabi, F., Benipal, H., Ahmad, A., Abbas, M., Vidug, K., & Holbrook, A. (2021). Drug‚Äìdrug interactions with warfarin: A systematic review and meta‚Äêanalysis. British journal of clinical pharmacology, 87(11), 4051-4100.

Xue, L., Singla, R. K., He, S., Arrasate, S., Gonz√°lez-D√≠az, H., Miao, L., & Shen, B. (2024). Warfarin‚ÄìA natural anticoagulant: A review of research trends for precision medication. Phytomedicine, 128, 155479.

Zhao, L., Zhai, Z., & Li, P. (2023). One rare warfarin resistance case and possible mechanism exploration. Pharmacogenomics and Personalized Medicine, 609-615.

---

## üë©‚Äçüî¨ Author

**Farah Yusri**  
Biomedical & Pharmacogenomics Enthusiast  
[LinkedIn](#) | [GitHub](#) | [Email](farahyusri12@gmail.com)
